Film formulations containing dexmedetomidine and methods of producing them
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
1. A self-supporting, dissolvable, film, comprising:
(i) dexmedetomidine hydrochloride;
(ii) one or more additional therapeutic agents;
(iii) a water-soluble hydroxypropyl cellulose polymer having a molecular weight about 40,000 daltons in an amount of about 3% to about 15% w/w of the total film weight;
(iv) a water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 140,000 daltons in an amount of about 3% to about 8% w/w of the total film weight;
(v) a water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 370,000 daltons in an amount of about 10% to about 50% w/w of the total film weight; and
(vi) water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons in an amount of about 40% to about 70% w/w of the total film weight, wherein (iii), (iv), (v), and (vi) form a single layer film substrate.
2. The film according to claim 1 , wherein dexmedetomidine hydrochloride is present in an amount of about 0.5 micrograms to about 200 micrograms.
3. The film according to claim 1 , wherein dexmedetomidine hydrochloride is present in an amount of about 5 micrograms to about 150 micrograms.
4. The film according to claim 1 , wherein dexmedetomidine hydrochloride is present in an amount of about 10 micrograms to about 60 micrograms.
5. The film according to claim 1 , wherein the one or more additional therapeutic agents is selected from the group consisting of opioid antagonists, opioid partial agonists, NMDA receptor antagonists, serotonin-norepinephrine reuptake inhibitors (SNRIs), and selective serotonin reuptake inhibitors (SSRIs).
6. The film according to claim 5 , wherein the one or more additional therapeutic agents is an opioid antagonist and the opioid antagonist is naltrexone or naloxone.
7. The film according to claim 6 , wherein the opioid antagonist is naltrexone.
8. The film according to claim 6 , wherein the opioid antagonist is present in an amount of about 0.5 mg to about 5 mg.
9. The film according to claim 6 , wherein the opioid antagonist is present in an amount of about 1 mg to about 3 mg.
10. The film according to claim 5 , wherein the one or more additional therapeutic agents is an opioid partial agonist and the opioid partial agonist is selected from the group consisting of buprenorphine, butorphanol, pentazocine, and tramadol.
11. The film according to claim 10 , wherein the opioid partial agonist is buprenorphine.
12. The film according to claim 10 , wherein the opioid partial agonist is present in an amount of about 2 mg to about 16 mg.
13. The film according to claim 10 , wherein the opioid partial agonist is present in an amount of about 4 mg to about 12 mg.
14. The film according to claim 5 , wherein the one or more additional therapeutic agents is an NMDA receptor antagonist and the NMDA receptor antagonist is ketamine.
15. The film according to claim 5 , wherein the one or more additional therapeutic agents is a serotonin-norepinephrine reuptake inhibitors and the serotonin-norepinephrine reuptake inhibitors is selected from the group consisting of amitriptyline, atomoxetine, desipramine, duloxetine, maprotiline, milnacipran, nefazodone, protriptyline, trimipramine, reboxetine, venlafaxine, and viloxazine.
16. The film according to claim 15 , wherein the serotonin-norepinephrine reuptake inhibitor is desipramine.
17. The film according to claim 5 , wherein the one or more additional therapeutic agents is a selective serotonin reuptake inhibitor and the selective serotonin reuptake inhibitor is selected from the group consisting of citalopram, fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, and escitalopram.
18. The film according to claim 17 , wherein the selective serotonin reuptake inhibitor is fluvoxamine.
19. The film according to claim 1 , wherein the dexmedetomidine hydrochloride and the one or more additional therapeutic agents are present in the single layer film substrate.
20. The film according to claim 19 , wherein the dexmedetomidine hydrochloride and the one or more additional therapeutic agents are substantially uniformly distributed throughout the single layer film substrate.
21. The film according to claim 1 , wherein the dexmedetomidine hydrochloride and the one or more additional therapeutic agents are present on one surface of the single layer film substrate.
22. The film according to claim 21 , wherein dexmedetomidine hydrochloride and the one or more additional therapeutic agents are present as individual discrete droplets on the surface of the film substrate.
23. The film according to claim 1 , further comprising one or more pharmaceutically acceptable carriers.
24. The film according to claim 23 , wherein the one or more pharmaceutically acceptable carriers j selected from the group consisting of liquid carriers, flavors, sweeteners, refreshing agents, pH adjusting agents, permeation enhancers, plasticizers, bulking agents, surfactants, anti-foaming agents, and colorants.
25. The film according to claim 1 , wherein the dexmedetomidine hydrochloride is present at about 0.05% to about 3% w/w of the total film weight.
26. The film according to claim 1 , wherein the disintegration time in the oral cavity is from about 15 seconds to about 180 seconds.
27. The film according to claim 26 , wherein the disintegration time in the oral cavity is from about 50 seconds to about 120 seconds.
28. The film according to claim 1 , wherein the film has a mucoadhesion force of 1000 g-2000 g.
29. The film according to claim 1 , wherein the film has a thickness of about 20 micrometers to about 200 micrometers and covers an area (width×length) of about 100 mm 2 to about 300 mm 2 .